We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.05%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$630M
AUM Growth
+$66.5M
Cap. Flow
+$74.6M
Cap. Flow %
11.85%
Top 10 Hldgs %
30.71%
Holding
120
New
23
Increased
22
Reduced
38
Closed
13

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$79.9M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.1M
3
MRK icon
Merck
MRK
+$12.3M
4
AGN
Allergan plc
AGN
+$6.72M
5
BMY icon
Bristol-Myers Squibb
BMY
+$6.42M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$20M
2
PFE icon
Pfizer
PFE
+$13.2M
3
MDT icon
Medtronic
MDT
+$11M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.02M
5
CPHD
Cepheid Inc
CPHD
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 86.01%
2 Financials 0.83%
3 Technology 0.09%
4 Energy 0.06%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
76
Neurocrine Biosciences
NBIX
$16.6B
$2.03M 0.32%
40,000
– –
ESPR
77
DELISTED
Esperion Therapeutics
ESPR
$1.8M 0.29%
130,000
-10,000
-7% -$113K
TNDM icon
78
Tandem Diabetes Care
TNDM
$1.56B
$1.79M 0.28%
23,400
+2,500
+12% +$182K
JNJ icon
79
Johnson & Johnson
JNJ
$625B
$1.77M 0.28%
+15,000
New +$1.82M
ICPT
80
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.65M 0.26%
+10,000
New +$1.58M
ACAD icon
81
Acadia Pharmaceuticals
ACAD
$5.03B
$1.59M 0.25%
50,000
– –
BHC icon
82
Bausch Health
BHC
$2.34B
$1.23M 0.2%
50,000
-160,000
-76% -$4.14M
TTPH
83
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.15M 0.18%
15,000
– –
RGLS
84
DELISTED
Regulus Therapeutics
RGLS
$990K 0.16%
2,500
-417
-14% -$172K
ANTH
85
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$945K 0.15%
37,500
– –
ADVM
86
DELISTED
Adverum Biotechnologies
ADVM
$633K 0.1%
15,401
– –
ATXS
87
DELISTED
Astria Therapeutics
ATXS
$616K 0.1%
1,667
-4,085
-71% -$1.08M
MD icon
88
Pediatrix Medical
MD
$2.2B
$596K 0.09%
9,000
-71,000
-89% -$4.86M
OREX
89
DELISTED
Orexigen Therapeutics, Inc.
OREX
$398K 0.06%
120,000
– –
MRTX
90
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$331K 0.05%
50,000
– –
CNCE
91
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$304K 0.05%
30,099
– –
OCUL icon
92
Ocular Therapeutix
OCUL
$2.02B
$275K 0.04%
40,000
– –
WFC icon
93
Wells Fargo
WFC
$264B
$200K 0.03%
+4,522
New +$216K
QCOM icon
94
Qualcomm
QCOM
$176B
$197K 0.03%
+2,869
New +$174K
CAT icon
95
Caterpillar
CAT
$387B
$193K 0.03%
+2,178
New +$178K
GKOS icon
96
Glaukos
GKOS
$10.6B
$192K 0.03%
5,100
– –
HAL icon
97
Halliburton
HAL
$26.6B
$190K 0.03%
+4,231
New +$185K
XOM icon
98
ExxonMobil
XOM
$634B
$183K 0.03%
+2,102
New +$186K
IBM icon
99
IBM
IBM
$224B
$182K 0.03%
+1,196
New +$181K
MSFT icon
100
Microsoft
MSFT
$3.71T
$181K 0.03%
+3,140
New +$177K
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2016 Portfolio in Review

As of Q3 2016, Rhenman & Partners Asset Management held 120 positions worth $630M, up 12% from $563M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $74.6M of net new capital in Q3 2016, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Shire pic: 409,858 shares worth $26.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 94% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $8.02M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2016 buy was Shire pic: 409,858 shares worth $26.6M.
  • Rhenman & Partners Asset Management added most to Allergan plc in Q3 2016, an estimated $6.72M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2016 reduction was Regeneron Pharmaceuticals, cutting an estimated $8.02M.
  • Rhenman & Partners Asset Management fully exited Gilead Sciences in Q3 2016, selling an estimated $20M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $630M portfolio in Q3 2016.
  • Rhenman & Partners Asset Management opened 23 new positions and closed 13 in Q3 2016.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $630M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2016, filed 8 Nov 2016.